10-Q: National Research Corporation Reports Q1 2024 Results: Revenue Declines Amidst Strategic Shifts

National Research Corporation's first quarter 2024 results show a decrease in revenue compared to the same period last year, alongside strategic adjustments in operations and investments.

Summary

• National Research Corporation, also known as NRC Health, reported a revenue of $35.3 million for the first quarter of 2024, a decrease of $1.2 million compared to the first quarter of 2023.
• The company experienced a decrease in US recurring revenue by $1.1 million, with 50% of this decline attributed to non-core solutions.
• Direct expenses saw a slight increase in variable costs by $67,000 due to higher data collection expenses, while fixed expenses decreased by $490,000 due to workforce reductions and automation.
• Selling, general, and administrative expenses decreased by $613,000 primarily due to reduced marketing expenses.
• Operating income decreased to $8.76 million from $9.016 million in the prior year, while the operating margin remained consistent at 25%.
• Total other expenses increased by $561,000 due to lower interest income and higher interest expenses from borrowings.
• The company's recurring contract value decreased by 5% to $139.5 million, primarily due to a lack of new contracts replacing losses.
• Cash provided by operating activities increased to $12.0 million, mainly due to working capital changes.
• The company repurchased 366,454 shares of common stock for $15.0 million during the quarter.
• Capital expenditures totaled $4.1 million, primarily for software development and building renovations.
• The company has $7 million outstanding on its line of credit and $18.5 million on its delayed draw term loan.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with some positive aspects like increased operating cash flow and expense management, but the negative aspects of declining revenue and recurring contract value, along with a working capital deficit, outweigh the positives, resulting in a slightly negative sentiment.

Positives

• Cash provided by operating activities increased significantly due to working capital changes.
• The company is actively managing expenses, with reductions in fixed direct costs and selling, general, and administrative expenses.
• The company continues to invest in software development for its Human Understanding solutions.
• The company has available borrowing capacity of $23 million on its line of credit and $56 million on its delayed draw term loan.
• The company is in compliance with its financial covenants.

Negatives

• Revenue decreased by $1.2 million compared to the same quarter last year.
• Recurring contract value decreased by 5%, indicating challenges in securing new contracts.
• The company experienced a working capital deficit of $28.8 million as of March 31, 2024.
• Total other expenses increased due to lower interest income and higher interest expenses.
• The company is experiencing a decline in US recurring revenue, particularly in non-core solutions.

Risks

• The company faces the risk of non-renewal of client service contracts and potential reductions in services purchased or prices.
• The healthcare market is highly competitive, with new market entrants and the possibility of increased price pressure.
• Economic downturns and consolidation in the healthcare industry could adversely affect the company's operations.
• The company is exposed to risks related to cyber-attacks, security breaches, and computer viruses.
• The company's intellectual property could be copied or independently developed by competitors.
• The company's ability to attract and retain key managers and other personnel is a risk.
• The company is exposed to the risk of failures or deficiencies in its information technology platform.
• The company is exposed to the risk of global conflicts affecting operations, sales, earnings, financial condition and liquidity.

Future Outlook

The company expects direct and selling, general, and administrative expenses to increase in future quarters due to restructuring and investments in its Human Understanding solutions. The company believes its existing sources of liquidity will be sufficient to meet its projected capital and debt maturity needs for the foreseeable future.

Management Comments

• The company's purpose is to humanize healthcare and support organizations in their understanding of each unique individual.
• The company's commitment to Human Understanding helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship.
• The company believes access to and analysis of its extensive consumer-driven information is increasingly valuable as healthcare providers need to better understand and engage the people they serve to create long-term relationships and build loyalty.

Industry Context

The healthcare industry is undergoing consolidation and evolving payment models, driving providers and payers towards more collaborative and integrated service models. NRC Health's cross-continuum positioning is increasingly important in this environment. The company's focus on patient and employee experience aligns with the industry's growing emphasis on value-based care and patient-centric approaches.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the decrease in recurring contract value suggests that NRC Health may be facing challenges in maintaining its market position compared to industry benchmarks.
• The company's operating margin of 25% is a key metric to compare against industry peers in the healthcare analytics and patient experience space, such as Press Ganey or Qualtrics, to assess its relative profitability.
• The increase in cash provided by operating activities is a positive sign, but it needs to be compared against the cash flow performance of similar companies to determine if it is above or below industry standards.
• The company's investment in software development for its Human Understanding solutions is a strategic move that should be compared against the technology investments of its competitors to assess its competitiveness in the long term.
• The company's debt levels and financial covenants should be compared against industry averages to assess its financial health and risk profile.

Management Changes

Legal Proceedings

• The company is involved in certain claims and litigation arising in the normal course of business, but does not believe the final disposition of these claims will have a material adverse effect on its financial position, results of operations, or liquidity.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and recurring contract value.
• Employees may be affected by the restructuring of service and technology areas.
• Customers may be impacted by the company's strategic shifts and investments in new solutions.
• Creditors may be monitoring the company's debt levels and financial covenants.

Next Steps

• The company plans to continue investing in its Human Understanding solutions.
• The company expects direct and selling, general, and administrative expenses to increase in future quarters.
• The company will continue to monitor its financial covenants and liquidity.

Key Dates

Keywords

healthcare analytics, patient experience, employee engagement, recurring contract value, subscription services, revenue, operating income, financial results, capital expenditures, share repurchase